# Endocrine Agents: Diabetes – Non-Insulin

**AUTHORIZATIONS:**  365 Days

**PRIOR AUTHORIZATION CRITERIA:**

Is there any reason the patient cannot be changed to a medication within the same class not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval

- Contraindication to or drug interaction with medications not requiring prior approval

- History of unacceptable/toxic side effects to medications not requiring prior approval

**NON-PREFERRED:**

1. There must have been a therapeutic failure of at least 60-day trial and failure with three preferred products

   Note: Inadequate clinical response after at least 60 days of recommended therapeutic dose with documented adherence to the regimen.

| **DIABETES – ORAL HYPOGLYCEMICS, SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITOR AND DPP-4** **COMBINATIONS** | |
|----------------------------------|-----------------------------------------|
| **PREFERRED**                    | **NON-PREFERRED**                        |
| No less than **90 days** of at least **one** preferred DPP-4 and SGLT product  | GLYXAMBI (empagliflozin/ linagliptin) |
|                                  |  QTERN (dapaglifozin-saxagliptin)                                           |
|                                  |  STEGLUJAN™ (ertugliflozin/sitagliptin)                                     |

Soliqua and Xultophy Request must address inability to use the individual components.
